Concerned about the entire class of COX-2 inhibitors, the FDA convened a joint session of their Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee on February 16, 17 and 18 to advise the FDA on the risk-benefit profile for these drugs.
FORBES: Vioxx and Diclofenac: Why Are Two Heart Risky Pain Drugs Viewed Differently?